- Previous Close
96.94 - Open
97.00 - Bid 98.04 x 800
- Ask 98.14 x 900
- Day's Range
96.82 - 98.35 - 52 Week Range
96.58 - 123.96 - Volume
3,134,932 - Avg. Volume
2,051,688 - Market Cap (intraday)
19.415B - Beta (5Y Monthly) 0.85
- PE Ratio (TTM)
22.15 - EPS (TTM)
4.43 - Earnings Date May 5, 2025
- Forward Dividend & Yield 0.96 (0.99%)
- Ex-Dividend Date Mar 31, 2025
- 1y Target Est
122.35
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
www.zimmerbiomet.comRecent News: ZBH
View More
Performance Overview: ZBH
Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZBH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZBH
View MoreValuation Measures
Market Cap
19.18B
Enterprise Value
24.86B
Trailing P/E
21.88
Forward P/E
11.78
PEG Ratio (5yr expected)
1.32
Price/Sales (ttm)
2.57
Price/Book (mrq)
1.54
Enterprise Value/Revenue
3.24
Enterprise Value/EBITDA
11.04
Financial Highlights
Profitability and Income Statement
Profit Margin
11.77%
Return on Assets (ttm)
4.65%
Return on Equity (ttm)
7.25%
Revenue (ttm)
7.68B
Net Income Avi to Common (ttm)
903.8M
Diluted EPS (ttm)
4.43
Balance Sheet and Cash Flow
Total Cash (mrq)
527.1M
Total Debt/Equity (mrq)
53.07%
Levered Free Cash Flow (ttm)
1.06B
Research Analysis: ZBH
View MoreResearch Reports: ZBH
View MoreMedical Device Industry: Swept Up in the Tariffs, Diabetes Device Makers Bear the Brunt
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
RatingPrice TargetMedical Device Industry: Swept Up in the Tariffs, Diabetes Device Makers Bear the Brunt
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
RatingPrice TargetProduct launches and M&A to drive 2025 growth
Based in Warsaw, Indiana, Zimmer Biomet is the nation's largest pure-play maker of orthopedic devices. The current company arose from the 2015 merger of Zimmer and Biomet, both of which were headquartered in Warsaw, Indiana. The company designs, develops, and manufactures reconstructive orthopedic implants, sports injury repair and trauma products, and related orthopedic surgical products. Its primary customers include musculoskeletal surgeons, neurosurgeons, hospitals, distributors, and, in their capacity as agents, healthcare purchasing organizations or buying groups. ZBH shares are a component of the S&P 500.
RatingPrice TargetThe markets are down at midday, with the Nasdaq lower by 2%. The Fed starts
The markets are down at midday, with the Nasdaq lower by 2%. The Fed starts its two-day meeting today with a call on rates due tomorrow. That part of the meeting is a non-event. No rate cut is expected. However, Wall Street will get a glimpse at the Fed's thinking through the Fed's quarterly 'dot plot' which comes out this round. The yield on the 10-year Treasury note is at 4.30%. Oil is at $68 per barrel. Bitcoin is near $81,700.